Benzinga | Sep 7, 2020 05:00PM EDT

Albireo to Announce Topline Results from Phase 3 Trial of Odevixibat for Treatment of PFIC on September 8, 2020

Albireo Pharma, Inc.(NASDAQ:ALBO) today announced that topline results from the PEDFIC 1 Phase 3 clinical trial evaluating the efficacy and safety of lead candidate odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC) will be announced September 8, 2020. Company management will host a conference call and live audio webcast at8:30 a.m. EDT to review the results.

To access the live conference call and webcast tomorrow,September 8, 2020, at8:30 a.m. EDT, please dial 877-407-0792 (domestic) or 201-689-8263 (international) and provide the access code 13709929. The live audio webcast of the presentation will be accessible from the Media & Investors page of Albireo's website,ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo's website for at least two weeks following the event.